1. Home
  2. CTOS vs IMNM Comparison

CTOS vs IMNM Comparison

Compare CTOS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Custom Truck One Source Inc.

CTOS

Custom Truck One Source Inc.

HOLD

Current Price

$9.77

Market Cap

2.3B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$23.44

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTOS
IMNM
Founded
1988
2006
Country
United States
United States
Employees
2500
N/A
Industry
Diversified Commercial Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.7B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CTOS
IMNM
Price
$9.77
$23.44
Analyst Decision
Buy
Strong Buy
Analyst Count
5
10
Target Price
$9.30
$32.80
AVG Volume (30 Days)
1.1M
839.6K
Earning Date
04-27-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
$6.84
N/A
Revenue Next Year
$4.86
$1,127.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.07
$7.15
52 Week High
$10.21
$27.65

Technical Indicators

Market Signals
Indicator
CTOS
IMNM
Relative Strength Index (RSI) 76.97 53.07
Support Level $5.50 $19.23
Resistance Level N/A $25.10
Average True Range (ATR) 0.39 0.98
MACD 0.15 -0.10
Stochastic Oscillator 88.76 35.04

Price Performance

Historical Comparison
CTOS
IMNM

About CTOS Custom Truck One Source Inc.

Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: